Also found in: Medical.
PAI-1Plasminogen Activator Inhibitor Type 1
PAI-1Type 1 Plasminogen Activator Inhibitor (gene)
References in periodicals archive ?
PAI-1 is the main inhibitor in the plasminogen activation system, which comprises an inactive proenzyme (plasminogen) that can be converted into its active form the plasmin, by the action of physiological plasminogen activators; plasmin is the main enzyme that degrades fibrin into soluble products (8).
In the present study, we investigated the regulation on KLF-4 and PAI-1 by TGF-[beta] in the murine lung epithelial LA-4 cells, then examined the expression of EMT-associated markers, such as Collagen I, [alpha]-SMA, and E-cadherin in the TGF-[beta]-treated LA-4 cells, and determined the influence on the TGF-[beta]-induced EMT by the PAI-1 knockdown or the KLF-4 overexpression.
Co-author Dr Steven Shea added that the human circadian system causes a morning peak in circulating levels of PAI-1, independent of any behavioural or environmental influences.
Hastanin genc yasta olmasi ve KAG'de yaygin trombuslu lezyonlari olmasi nedeniyle birinci haftada dis merkezde yapilan genetik incelemesinde PAI-1 4G/4G mutasyonu oldugu tespit edildi.
Clinical characteristics, fibrinogen, PAI-1, tPA and hsCRP levels between the controls and CAD patients were noted (Table-1).
Del total de proteinas secretadas por celulas endoteliales en cultivo, el PAI-1 representa el 12.
More specifically, plasminogen, tPA/uPA, and PAI-1 initially increase expression in skeletal muscle following muscle injury in animals (22).
In the present study, we attempted to investigate the mRNA expression of PAI-1 and tPA in maternal peripheral blood from women suffering from preeclampsia, compared with age-matched controls.
Because t-PA and PAI-1 are produced by the endothelium, regulation of their synthesis and secretion at the EC level represents a rapid and a direct way of modulating the fibrinolytic potential of blood.
Women at risk for preeclampsia had a high PAI-1 to PAI-2 ratio, but antioxidant supplements raised PAI-2 levels and improved the ratio.
Anita Prechtl and her colleagues at the Technical University of Munich measured uPA and PAI-1 concentrations in tumor tissue from 556 breast cancer patients with no detectable cancer in their lymph nodes.